Invivyd, Inc. financial data

Symbol
IVVD on Nasdaq
Location
1601 Trapelo Road, Suite 178, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Adagio Therapeutics, Inc. (to 9/12/2022)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 376 % -69.3%
Quick Ratio 16.1 %
Debt-to-equity 35.2 % +276%
Return On Equity -155 % -177%
Return On Assets -115 % -124%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 120M shares +8.63%
Common Stock, Shares, Outstanding 120M shares +8.88%
Entity Public Float 67.1M USD -70.6%
Common Stock, Value, Issued 12K USD +9.09%
Weighted Average Number of Shares Outstanding, Basic 119M shares +8.88%
Weighted Average Number of Shares Outstanding, Diluted 119M shares +8.88%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 9.3M USD
Research and Development Expense 182M USD +56.1%
Costs and Expenses 71.6M USD +66.3%
Operating Income (Loss) -234M USD -27.2%
Nonoperating Income (Expense) 9.26M USD -36.8%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -225M USD -32.8%
Earnings Per Share, Basic -1.96 USD/shares -26.5%
Earnings Per Share, Diluted -1.96 USD/shares -26.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 107M USD -41.2%
Accounts Receivable, after Allowance for Credit Loss, Current 8.15M USD
Inventory, Net 27.1M USD
Assets, Current 151M USD -44.1%
Property, Plant and Equipment, Net 1.64M USD -18.1%
Operating Lease, Right-of-Use Asset 1.73M USD -34.1%
Other Assets, Noncurrent 7.45M USD +3885%
Assets 162M USD -41.1%
Accounts Payable, Current 17.7M USD +93.1%
Accrued Liabilities, Current 59.4M USD +272%
Liabilities, Current 78.5M USD +193%
Operating Lease, Liability, Noncurrent 219K USD -76.4%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 78.8M USD +177%
Accumulated Other Comprehensive Income (Loss), Net of Tax -18K USD -800%
Retained Earnings (Accumulated Deficit) -884M USD -34.2%
Stockholders' Equity Attributable to Parent 83.2M USD -66.3%
Liabilities and Equity 162M USD -41.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -50.2M USD -21.9%
Net Cash Provided by (Used in) Financing Activities 39.1M USD +7114%
Net Cash Provided by (Used in) Investing Activities -140K USD -100%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 120M shares +8.88%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.3M USD -133%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 107M USD -41.2%
Deferred Tax Assets, Valuation Allowance 200M USD +52.6%
Deferred Tax Assets, Gross 201M USD +52.1%
Operating Lease, Liability 435K USD +0.69%
Depreciation 122K USD +1.67%
Payments to Acquire Property, Plant, and Equipment 140K USD -77.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -225M USD -32.7%
Operating Lease, Liability, Current 1.41M USD -13.7%
Deferred Tax Assets, Operating Loss Carryforwards 76.4M USD +24%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Operating Lease, Payments 435K USD +0.69%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 699K USD -21.9%
Share-based Payment Arrangement, Expense 21.1M USD +4.11%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%